Tests diet and semaglutide for fatty liver disease linked to obesity
Compares dietitian-guided nutrition with semaglutide in adults with obesity and fatty liver.
Plain-language title generated from the registry record
Registry title: Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Key facts
- Where
- Québec, CanadaSee the site
Where in Canada
- Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec - Université LavalQuébec, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
- Trial code
- NCT06764056
- Record updated
- 8 January 2025
- Original description
The goal of this clinical trial is to improve the treatment of hepatic steatosis associated with obesity with pharmacological and nutritionnal approaches. The main question it aims to answer is:Read full original descriptionShow less
Characterization and Management of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Through an Individualized Nutritionnal Approach and Semaglutide Therapy.
The goal of this clinical trial is to improve the treatment of hepatic steatosis associated with obesity with pharmacological and nutritionnal approaches. The main question it aims to answer is:
Does an individualized nutritionnal approach with a dietician combined with medication targeting obesity is the most efficient way to treat hepatic steatosis associated with obesity?
Participants will either participate in one of three groups:
* Nutrition: Participant will only have a regular follow-up with a registered dietician; * Nutrition + Semaglutide: Participants will start a new medication targeting obesity and will have a regular follow-up with a registered dietician; * Semaglutide: Participants will start a new medication targeting obesity.
Inclusion: Body mass index between 30 and 50 kg/m2; Stade 2 or 3 (S2 or S3) hepatic steatosis with or without liver fibrosis.
Exclusion: Bariatric surgery; Type 1 diabetes diagnosis; Known chronic hepatic disease non-steatotic at the entry of the study (Wilson's disease, hemochromatosis, alpha-1-antitrypsin deficiency, viral hepatitis, auto-immune hepatitis, etc.); Gastro-intestinal pathologies (GI cancers, IBD, etc.); Alcohol consumption exceeding recommendations [>140 g/week (women) and >210 g/week (men)]; Pharmacological treatment targeting obesity active or ended in the last 3 months; Capsulated probiotics consumption; Antibiotic treatment in the last 3 months; Pregnancy; Cirrhosis diagnosis (hepatic decompensation).